BIOMAT Database Logo BIOMAT Database Logo

Effects of proteolytic degradation products of human fibrinogen and of human factor VIII on platelet aggregation and vascular permeability. 1979

J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć

UI MeSH Term Description Entries
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D012103 Batroxobin A proteolytic enzyme obtained from the venom of fer-de-lance (BOTHROPS ATROX). It is used as a plasma clotting agent for fibrinogen and for the detection of fibrinogen degradation products. The presence of heparin does not interfere with the clotting test. Hemocoagulase is a mixture containing batroxobin and factor X activator. EC 3.4.21.-. Defibrol,Hemocoagulase,Defibrase,Reptilase,Reptilase-DEF,Reptilase DEF
D002199 Capillary Permeability The property of blood capillary ENDOTHELIUM that allows for the selective exchange of substances between the blood and surrounding tissues and through membranous barriers such as the BLOOD-AIR BARRIER; BLOOD-AQUEOUS BARRIER; BLOOD-BRAIN BARRIER; BLOOD-NERVE BARRIER; BLOOD-RETINAL BARRIER; and BLOOD-TESTIS BARRIER. Small lipid-soluble molecules such as carbon dioxide and oxygen move freely by diffusion. Water and water-soluble molecules cannot pass through the endothelial walls and are dependent on microscopic pores. These pores show narrow areas (TIGHT JUNCTIONS) which may limit large molecule movement. Microvascular Permeability,Permeability, Capillary,Permeability, Microvascular,Vascular Permeability,Capillary Permeabilities,Microvascular Permeabilities,Permeabilities, Capillary,Permeabilities, Microvascular,Permeabilities, Vascular,Permeability, Vascular,Vascular Permeabilities
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005169 Factor VIII Factor VIII of blood coagulation. Antihemophilic factor that is part of the factor VIII/von Willebrand factor complex. Factor VIII is produced in the liver and acts in the intrinsic pathway of blood coagulation. It serves as a cofactor in factor X activation and this action is markedly enhanced by small amounts of thrombin. Coagulation Factor VIII,Factor VIII Clotting Antigen,Factor VIII Coagulant Antigen,Factor VIII Procoagulant Activity,Thromboplastinogen,Blood Coagulation Factor VIII,F VIII-C,Factor 8,Factor 8 C,Factor Eight,Factor VIIIC,Hyate-C,Hyatt-C,F VIII C,Hyate C,HyateC,Hyatt C,HyattC
D005337 Fibrin A protein derived from FIBRINOGEN in the presence of THROMBIN, which forms part of the blood clot. Antithrombin I
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
Factor VIII and human platelet aggregation. IV. Effect of proteolytic enzymes on platelet aggregation by factor VIII.
October 1976, British journal of haematology,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
Fibrinogen degradation products and platelet aggregation.
January 1967, Thrombosis et diathesis haemorrhagica. Supplementum,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
Singlet oxygen inactivates fibrinogen, factor V, factor VIII, factor X, and platelet aggregation of human blood.
March 2000, Thrombosis research,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
Inhibition of platelet aggregation by dialysable fibrinogen degradation products (FDP).
February 1970, Thrombosis et diathesis haemorrhagica,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
Action of fibrinogen degradation products and fibrin monomer soluble complexes on platelet aggregation.
January 1971, Scandinavian journal of haematology. Supplementum,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
INFLUENCE OF FIBRINOGEN DEGRADATION PRODUCTS (FDP) ON PLATELET AGGREGATION, ADHESIVENESS AND VISCOUS METAMORPHOSIS.
January 1964, Thrombosis et diathesis haemorrhagica,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
Lipolytic versus proteolytic degradation of human factor VIII.
March 1977, Thrombosis research,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
Factor VIII and human platelet aggregation. II. Characteristics of aggregation of human platelets by bovine factor VIII.
October 1976, British journal of haematology,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
[Platelet aggregation by ADP in the presence of fibrinogen degradation products].
January 1969, Nouvelle revue francaise d'hematologie,
J Stachurska, and S Lopaciuk, and B Gerdin, and T Saldeen, and A Korościk, and M Kopeć
Factor VIII and human platelet aggregation. III. Further studies on aggregation of humna platelets by neuraminidase-treated human factor VIII.
October 1976, British journal of haematology,
Copied contents to your clipboard!